Newron Pharmaceuticals SpA has held initial discussions with potential partners about licensing an experimental drug to treat schizophrenia, a mental health condition with no cure. “We see a good chance of a licensing deal in the second half of the year,” Chief Executive Officer Stefan Weber said in a telephone interview late on Tuesday.